Suppression of growth hormone (GH) secretion by a selective GH-releasing hormone (GHRH) antagonist. Direct evidence for involvement of endogenous GHRH in the generation of GH pulses.

Jaffe CA, Friberg RD, Barkan AL

The Journal of clinical investigation1 Aug 1993Cited by 47 (Europe PMC)

PMID8349808PMCIDPMC294903DOI10.1172/jci116639PepBankPUB-08349808

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Sermorelin.

01HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome
In six healthy young men, the GHRH antagonist suppressed integrated total GH secretion by 40%.
In plain wordsIn healthy young men, a GHRH blocker lowered total overnight GH release.
Peptide
Sermorelin
Outcome
DecreaseIntegrated total GH secretion
Study
n = 6
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Suppression of integrated total GH secretion
40%
GHRH-Ant 400 micrograms/kg
Source sentences
Summary
Integrated total and pulsatile GH secretion were suppressed during GHRH-Ant treatment by 40 +/- 6 (SE) %
1 context sentence(design, population, supporting numbers)
Summary · context
Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0834980801
02HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome
In six healthy young men, the GHRH antagonist suppressed integrated pulsatile GH secretion by 75%.
In plain wordsIn healthy young men, a GHRH blocker lowered GH release in pulses.
Peptide
Sermorelin
Outcome
DecreaseIntegrated pulsatile GH secretion
Study
n = 6
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Suppression of integrated pulsatile GH secretion
75%
GHRH-Ant 400 micrograms/kg
Source sentences
Summary
Integrated total and pulsatile GH secretion were suppressed during GHRH-Ant treatment by 40 +/- 6 (SE) % and 75 +/- 5%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0834980802
03HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome
The GHRH antagonist suppressed maximum GH pulse amplitude versus vehicle.
In plain wordsIn healthy young men, a GHRH blocker lowered the peak size of GH pulses.
Peptide
Sermorelin
Outcome
DecreaseMaximum GH pulse amplitude
Study
n = 6
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Maximum GH pulse amplitude
1.8 micrograms/liter
GHRH-Ant
Source sentences
Summary
GHRH-Ant suppressed maximum (7.6 +/- 2.2 vs 1.8 +/- 0.5 micrograms/liter; P < 0.001)
1 context sentence(design, population, supporting numbers)
Summary · context
Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0834980803
04HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome
The GHRH antagonist suppressed mean GH pulse amplitude versus vehicle.
In plain wordsIn healthy young men, a GHRH blocker lowered the average size of GH pulses.
Peptide
Sermorelin
Outcome
DecreaseMean GH pulse amplitude
Study
n = 6
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Mean GH pulse amplitude
1.1 micrograms/liter
GHRH-Ant
Source sentences
Summary
and mean (3.3 +/- 1.0 vs 1.1 +/- 0.2 micrograms/liter; P = 0.02)
1 context sentence(design, population, supporting numbers)
Summary · context
Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0834980804
05HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome
The GHRH antagonist did not change integrated nonpulsatile GH levels.
In plain wordsIn healthy young men, a GHRH blocker did not change non-pulsatile GH levels.
Peptide
Sermorelin
Outcome
No significant changeIntegrated nonpulsatile GH
Study
n = 6
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
There was no change in integrated nonpulsatile GH levels
1 context sentence(design, population, supporting numbers)
Summary · context
Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0834980805
06HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome
The GHRH antagonist did not change GH pulse frequency.
In plain wordsIn healthy young men, a GHRH blocker did not change how often GH pulses occurred.
Peptide
Sermorelin
Outcome
No significant changeGH pulse frequency
Study
n = 6
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
There was no change in integrated nonpulsatile GH levels, pulse frequency
1 context sentence(design, population, supporting numbers)
Summary · context
Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0834980806
07HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome
The GHRH antagonist did not change interpulse GH concentration.
In plain wordsIn healthy young men, a GHRH blocker did not change GH levels between pulses.
Peptide
Sermorelin
Outcome
No significant changeInterpulse GH concentration
Study
n = 6
Comparator
Vehicle
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Source sentences
Summary
There was no change in integrated nonpulsatile GH levels, pulse frequency, or interpulse GH concentration.
1 context sentence(design, population, supporting numbers)
Summary · context
Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0834980807
08HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome
The GHRH antagonist suppressed GH responses to GHRH boluses of 0.33 micrograms/kg given 1, 6, 12 and 24 h later by 95, 81, 59 and 4%, respectively.
In plain wordsIn healthy young men, a GHRH blocker reduced the GH response to a GHRH dose, with the effect fading over 24 hours.
Peptide
Sermorelin
Outcome
DecreaseGH response to GHRH 0.33 micrograms/kg boluses
Study
n = 6
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Suppression of GH response
95%
1 h after GHRH-Ant
Suppression of GH response
81%
6 h after GHRH-Ant
Suppression of GH response
59%
12 h after GHRH-Ant
Suppression of GH response
4%
24 h after GHRH-Ant
Source sentences
Summary
GHRH-Ant 400 micrograms/kg also suppressed the GH responses to intravenous boluses of GHRH 0.33 micrograms/kg given 1, 6, 12, and 24 h later by 95, 81, 59, and 4%, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0834980808
09HumanNot a test of Sermorelin aloneNon-randomized trialEfficacy outcome
In five healthy men, the GHRH antagonist suppressed responses to 10-fold larger GHRH boluses (3.3 micrograms/kg) by 82% at 1 h and 0% at 6 h.
In plain wordsIn healthy men, a GHRH blocker reduced the GH response to a larger GHRH dose at 1 hour but not at 6 hours.
Peptide
Sermorelin
Outcome
DecreaseGH response to GHRH 3.3 micrograms/kg boluses
Study
n = 5
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Suppression of GH response
82%
1 h after GHRH-Ant
Suppression of GH response
0%
6 h after GHRH-Ant
Source sentences
Summary
In five healthy men, the responses to 10-fold larger GHRH boluses (3.3 micrograms/kg) were suppressed by 82 and 0%, 1 and 6 h after GHRH-Ant 400 micrograms/kg, respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
Six healthy young men were given a bolus injection of GHRH-Ant 400 micrograms/kg body wt or vehicle at 2200 h and nocturnal GH concentrations were assessed by every 10-min blood sampling until 0800 h.
In this study, Sermorelin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Sermorelin.
Report a problemFND-0834980809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 10:21 UTC
Study results updated
Version 1
9 Oct 2026, 03:13 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.